Financial News

Financial Report: Amgen

1Q revenues up 10%

Amgen

1Q Revenues: $5.5 billion (+10%)

1Q Earnings: $1.9 billion (+17%)

Comments: Sales growth was driven by Enbrel (+24% to $1.4 billion), Prolia (+29% to $352 million), Aranesp (+11% to $532 million), Neulasta (+4% to $1.2 billion), Kyprolis (+43% to $154 million), and XGEVA (+11% to $378 million). EPOGEN and NEUPOGEN sales were down 44% and 13% respectively, due to biosimilar competition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters